By: Chris Ryan From: onclive.com The FDA has approved vepdegestrant (Veppanu) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least 1 line of endocrine therapy.1,2 The approval was backed by data from the phase 3 VERITAC-2 trial (NCT05654623), which demonstrated …
Vepdegestrant Demonstrates Progression-Free Survival in Patients With ER+/HER2- Metastatic Breast Cancer
From: pharmacytimes.com Vepdegestrant (ARV-471; Arvinas, Inc) met its primary end point of progression-free survival (PFS) compared with fulvestrant (Faslodex; AstraZeneca) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with CDK 4/6 inhibitors and endocrine therapy. The clinically meaningful outcomes were observed in the phase …